We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GLMD:NASDAQGalmed Pharmaceuticals Ltd. Analysis

Data as of 2026-08-08 - not real-time

$0.60

Latest Price

9/10Risk

Risk Level: High

Executive Summary

At $0.6019, Galmed Pharmaceuticals Ltd. shows a bearish moving-average alignment, with shorter averages beneath longer ones. It has gained 4.9% over the past 30 days. Relative strength is 56.0 — neutral — and the MACD signal is bullish. Watch $0.4570 as support and $0.6210 as the nearer resistance level.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 84.9%, a beta of 1.74 and a maximum drawdown of 70.9%, position sizing matters more than entry timing here. Thin trading volumes mean execution costs can be material on larger orders. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
This one splits by horizon — sell in the near term, hold further out, at 3/10 long-term conviction.

Top Market Events

Barron's8dGalmed Pharmaceuticals Ltd.Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical...ADVFN22dGalmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline NASDAQ:GLMD Galmed...1dGalmed Pharmaceuticals Ltd.View Galmed Pharmaceuticals Ltd. GLMD stock quote prices, financial information, real-time...

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 0.74
  • MACD momentum is positive

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 0.74
  • 30-day volatility of 84.9%

Long Term

> 3 years
Neutral
Model confidence: 3/10

Key Factors

  • Negative return on equity of -72.1%
  • Negative free cash flow
  • 30-day volatility of 84.9%

Key Metrics & Analysis

Financial Health

P/E Ratio-0.6
ROE-72.12%
ROA-33.46%
P/B Ratio0.3
Op. Cash Flow$-7684000
Free Cash Flow$-4989625
Industry P/E29.5

Technical Analysis

TrendBearish
RSI56.0
Support$0.46
Resistance$0.62
MA 20$0.55
MA 50$0.58
MA 200$0.74
MACDBullish
VolumeDecreasing
Fear & Greed Index94.82

Valuation

GradeFair
TypeBlend

Risk Assessment

Beta1.74
Volatility84.85%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.